Genomic Differences in Thyroid Cancers From Primary Sites Versus Distant Metastases in Individual Patients: A Clinical Perspective and Preliminary Report.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 4/4)
유사 논문P · Population 대상 환자/모집단
29 patients were analyzed, identifying 16 mutations and 4 fusions, including two novel fusions (FGFR2-SHTN1 and RFTN1-BRAF).
I · Intervention 중재 / 시술
Genomic Differences in Thyroid Cancers From Primary Sites
C · Comparison 대조 / 비교
Distant Metastases in Individual Patients
O · Outcome 결과 / 결론
A longer time interval between specimen acquisitions was significantly associated with genetic discrepancies (p = 0.032). [CONCLUSION] Patterns of genetic discrepancies between primary and metastatic TC vary, offering valuable insights for clinical practice.
[BACKGROUND] Distant metastasis is a leading cause of thyroid cancer (TC)-related deaths.
- p-value p = 0.032
APA
Lin YB, Hu HW, et al. (2025). Genomic Differences in Thyroid Cancers From Primary Sites Versus Distant Metastases in Individual Patients: A Clinical Perspective and Preliminary Report.. Head & neck, 47(7), 1907-1927. https://doi.org/10.1002/hed.28100
MLA
Lin YB, et al.. "Genomic Differences in Thyroid Cancers From Primary Sites Versus Distant Metastases in Individual Patients: A Clinical Perspective and Preliminary Report.." Head & neck, vol. 47, no. 7, 2025, pp. 1907-1927.
PMID
39936351 ↗
Abstract 한글 요약
[BACKGROUND] Distant metastasis is a leading cause of thyroid cancer (TC)-related deaths. Genetic profiling is typically limited to one sample per patient due to cost and sampling-risk concerns. Differences between samples from thyroid and distant metastasis within individual patients are unclear.
[METHODS] Patients with TC and distant metastasis were recruited for genetic analysis.
[RESULTS] Using a TC-specific NGS panel, 66 specimens from 29 patients were analyzed, identifying 16 mutations and 4 fusions, including two novel fusions (FGFR2-SHTN1 and RFTN1-BRAF). Genetic alterations differed between primary and metastatic sites in nine patients (31%), predominantly in additional oncogenic alterations (89%). More genetic alterations were found at the primary site in three patients and metastatic sites in four. Distinct mutations were found in two patients. A longer time interval between specimen acquisitions was significantly associated with genetic discrepancies (p = 0.032).
[CONCLUSION] Patterns of genetic discrepancies between primary and metastatic TC vary, offering valuable insights for clinical practice.
[METHODS] Patients with TC and distant metastasis were recruited for genetic analysis.
[RESULTS] Using a TC-specific NGS panel, 66 specimens from 29 patients were analyzed, identifying 16 mutations and 4 fusions, including two novel fusions (FGFR2-SHTN1 and RFTN1-BRAF). Genetic alterations differed between primary and metastatic sites in nine patients (31%), predominantly in additional oncogenic alterations (89%). More genetic alterations were found at the primary site in three patients and metastatic sites in four. Distinct mutations were found in two patients. A longer time interval between specimen acquisitions was significantly associated with genetic discrepancies (p = 0.032).
[CONCLUSION] Patterns of genetic discrepancies between primary and metastatic TC vary, offering valuable insights for clinical practice.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.